Celltrion셀트리온
068270 · KOSPI · ₩CELLTRION · 셀트리온
Broker reports
| Date | Broker | Report | Rating | Target | Change | Upside | Since publish | Read |
|---|---|---|---|---|---|---|---|---|
| Oct 6 | Heungkuk Securities | [Pharma/Bio/Cosmetics] Celltrion - Solid Earnings Growth Outlook | — | — | — | +3.8% | Read ↗ |
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
Reported in the news
| Date | Broker | Target | Change | Rating | Source |
|---|---|---|---|---|---|
| Oct 27 | — | — | Raised | — | Reported by Seoul Economic Daily |
| Oct 27 | — | ₩270,000 | Maintained | — | Reported by The Financial News |
| Oct 27 | NH Investment & Securities | +11% | Raised | — | Reported by Edaily |
| Oct 27 | NH Investment & Securities | +11% | Raised | — | Reported by Edaily |
| Oct 22 | — | ₩290,000 | Raised | — | Reported by Seoul Economic Daily |
| Oct 22 | — | ₩260,000 | — | Reported by The Financial News | |
| Oct 22 | Daol Investment & Securities | — | Raised | — | Reported by Yonhap News Agency |
| Oct 22 | — | — | Raised | — | Reported by Maeil Business Newspaper |
Target prices and ratings as news headlines report them, for every broker, including the ones whose reports we don't collect. Only what the headline says; open the article for the rest. Not financial advice.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
Celltrion reported record third-quarter revenue and operating profit, with the shares trading well below their 52-week high.
Celltrion, a Korean biosimilar maker, posted record Q3 2026 revenue of ₩1.5755T and operating profit of ₩525.3B, according to preliminary results and press coverage. On a trailing twelve-month basis to H1 2026 it reports revenue of ₩4.90T, a 31.7% operating margin and a 32.2% net margin, and the stock closed at ₩190,000 on 2026-10-26, about 24% below its 52-week high of ₩251,000.
What stands out
- Q3 revenue of ₩1.5755T was up 53% year on year and operating profit of ₩525.3B was up 74.3%, per press reports of the preliminary results.
- Trailing revenue of ₩4.90T is well above 2025 full-year revenue of ₩4.16T, while trailing operating margin of 31.7% is above the 28.1% reported for 2025.
- The company carries ₩3.88T of borrowings against ₩1.08T of cash, and trailing return on equity is 8.9%, below its 2021 level of 14.8%.
- The valuation model's base-case DCF value is ₩111,325 per share, well below the current price, while the bull case is ₩175,889 and the bear case is ₩71,995; the model uses a 7.2% discount rate.
- Recent headlines point to new US supply deals for Omlyclo and Aptozma, and the filings show a share buyback decision and a share cancellation decision in the past two months.
What to watch
- The amended preliminary Q3 earnings filing dated 2026-10-27, and whether the final quarterly figures differ from the preliminary numbers.
- Execution of the buyback programme and the reported higher investment spending, which press coverage links to margins.
- Foreign ownership, which has risen to 25.7% from 24.8% over 60 days, while retail investors were net sellers of about ₩356B over the last 20 days.
Data as of Oct 26, 2026 · written 3d ago
This is not financial advice.
Also known as: Celltrion / 셀트리온 / 068270 / KRX:068270
Source: KRX statistical information